1013941-02-0

Basic information

• Product Name: 3-benzyl-15β-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-estrone
• Synonyms: 3-benzyl-15β-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-estrone
• CAS NO: 1013941-02-0
• Molecular Weight: 544.775
• Mol File: 1013941-02-0.mol

Chemical Properties

• CAS DataBase Reference: 3-benzyl-15β-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-estrone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-15β-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-estrone(1013941-02-0)
• EPA Substance Registry System: 3-benzyl-15β-[6-(tetrahydro-pyran-2-yloxy)-hexyl]-estrone(1013941-02-0)

Safety Data

• Hazardous Substances Data: 1013941-02-0(Hazardous Substances Data)

Upstream product

• 117021-10-0 1-[(tetrahydro-2H-pyran-2-yl)oxy]-6-hexylmagnesium bromide 
• 138743-03-0 (14α)-3-benzyloxy-1,3,5(10),15-estratetraen-17-one 
• 53963-10-3 2-[(6-bromohexyl)oxy]tetrahydro-2H-pyran 

Relevant articles and documents

Therapeutically Active Triazoles and Their Use

Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.

THERAPEUTICALLY ACTIVE TRIAZOLES AND THEIR USE

This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17beta-hydroxysteroid dehydrogenase (17beta-HSD) such as 17beta-HSD type 1, type 2 or type 3 enzyme.